10-Q: PROCEPT BioRobotics Reports Strong Revenue Growth in Second Quarter 2024, Driven by Increased Adoption of Aquablation Therapy

PROCEPT BioRobotics Corporation announced a 70% increase in revenue for the six months ended June 30, 2024, driven by increased sales of their AquaBeam Robotic System and related consumables.

Summary

• PROCEPT BioRobotics Corporation reported a significant increase in revenue for the second quarter of 2024, reaching $53.4 million, a 61% increase compared to the same period in 2023.
• For the six months ended June 30, 2024, revenue totaled $97.9 million, a 70% increase compared to $57.5 million in the first half of 2023.
• The company's gross margin improved to 59% in the second quarter of 2024, up from 56% in the same period of 2023, and 58% for the six months ended June 30, 2024, up from 54% in the same period of 2023.
• The company's net loss for the second quarter was $25.6 million, similar to the $25.3 million loss in the second quarter of 2023.
• The net loss for the six months ended June 30, 2024 was $51.6 million, compared to a net loss of $53.8 million for the same period in 2023.
• As of June 30, 2024, PROCEPT had an install base of 516 AquaBeam Robotic Systems globally, with 400 located in the United States.
• The company had cash and cash equivalents of $214.1 million as of June 30, 2024, and an accumulated deficit of $506.2 million.

Sentiment

Score: 7

Explanation: The document shows strong revenue growth and improving gross margins, which are positive indicators. However, the company is still operating at a loss and has a significant accumulated deficit, which tempers the overall positive sentiment. The company's future success depends on continued market adoption and effective cost management.

Positives

• The company experienced substantial revenue growth, driven by increased sales of both systems and handpieces.
• Gross margin improvements indicate better cost management and pricing strategies.
• The growing install base of AquaBeam Robotic Systems suggests increasing market adoption.
• The company has a strong cash position to support future growth and operations.
• The company has a significant body of clinical evidence supporting the benefits of Aquablation therapy, with approximately 150 peer-reviewed publications.

Negatives

• The company continues to operate at a net loss, although the loss is slightly reduced compared to the previous year.
• Operating expenses, particularly in research and development and selling, general, and administrative, remain high.
• The company has an accumulated deficit of $506.2 million.

Risks

• The company's future performance depends on continued market acceptance of Aquablation therapy.
• The company's ability to manage costs and scale manufacturing operations efficiently will impact profitability.
• The company's success is dependent on reimbursement and coverage decisions by third-party payors.
• The company is exposed to risks from changes in interest rates due to its loan facility.
• The company is exposed to foreign currency risk due to international sales and expenses.

Future Outlook

The company believes that its existing cash and cash equivalents, along with anticipated revenue, will be sufficient to fund operations for at least the next twelve months. They plan to continue investing in sales, marketing, operations, and research and development to drive future growth.

Management Comments

• Management is focused on driving adoption of Aquablation therapy and increasing system utilization.
• Management expects revenue to increase as the install base of AquaBeam Robotic Systems grows.
• Management anticipates gross margin to increase over the long term as production volume increases.
• Management plans to leverage treatment data and software development capabilities to integrate artificial intelligence and machine learning.

Industry Context

The company operates in the surgical robotics market, specifically targeting the urology sector with its Aquablation therapy for BPH. The market is competitive, with other surgical interventions available for BPH. The company's focus on minimally invasive procedures and its strong clinical evidence base positions it well for growth in this market.

Comparison to Industry Standards

• Intuitive Surgical, a leader in surgical robotics, reported a gross profit margin of 67.5% in their most recent quarter, which is higher than PROCEPT's 58%.
• Globus Medical, another player in the medical device space, reported a gross profit margin of 72.5% in their most recent quarter, also higher than PROCEPT's.
• While PROCEPT's revenue growth is strong, its gross margin is lower than some established competitors, indicating potential for improvement in cost management and pricing strategies.
• The company's focus on a specific niche (BPH treatment) may allow for more targeted growth compared to companies with broader product portfolios.

Stakeholder Impact

• Shareholders will be impacted by the company's revenue growth and financial performance.
• Employees will be impacted by the company's growth and expansion.
• Customers (hospitals and urologists) will benefit from the company's innovative technology.
• Suppliers will be impacted by the company's increasing production volumes.
• Creditors will be impacted by the company's financial performance and debt obligations.

Next Steps

• The company plans to continue expanding its sales and marketing efforts.
• The company will continue to invest in research and development to enhance its products and technologies.
• The company will focus on increasing system utilization within hospitals.
• The company will continue to engage with commercial payors to establish positive national and regional coverage policies.

Key Dates

Keywords

Aquablation, Robotics, Urology, BPH, Surgical Robotics, Medical Devices, Healthcare, AquaBeam, Prostate, Revenue Growth